FDA recommends use in early-stage disease To view this email as a web page,
click here By Noah Higgins-Dunn After facing intense pushback, Biogen on Thursday said the FDA approved an updated label for its Alzheimer's drug Aduhelm that recommends the amyloid-beta targeting antibody for patients with mild cognitive impairment or mild dementia. read more |
| |
---|
| | |